StockData

Arcutis Biotherapeutics vs Zai Lab

ARQT and ZLAB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ARQT and ZLAB compare

Zai Lab is the larger company, worth 11 times as much as Arcutis Biotherapeutics ($36.5B against $3.4B).

Arcutis Biotherapeutics grew revenue faster over the last twelve months (76.1% versus 5.1% for Zai Lab).

Arcutis Biotherapeutics keeps more of each dollar of sales as profit, with a net margin of 6.1% compared with −41.9% at Zai Lab.

Arcutis Biotherapeutics scores higher on the StockData Score (11 against 7 for Zai Lab), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricARQTZLAB
Size and price
Market cap$3.4B$36.5B
Share price$27.15$23.47
Change, 1 year18.8%8.0%
Change, 5 years62.9%−69.5%
Beta (5Y)1.171.46
Employees3541,784
StockData Score
Total score11 (better)7
Valuation score00
Growth score4 (better)1
Performance score4 (better)3
Health score33
Dividend score00
Valuation
P/E123×–
P/S7.4× (better)81.1×
P/B15.5× (better)60.0×
EV/EBITDA95.8×–
P/FCF87.2×–
FCF yield1.1% (better)−0.38%
Fair value$5.46$4.52
Margin of safety−397% (better)−420%
Growth
Revenue growth (TTM)76.1% (better)5.1%
Revenue growth, 5Y average–56.5%
Profitability
Gross margin91.1% (better)56.5%
Operating margin7.4% (better)−58.7%
Net margin6.1% (better)−41.9%
FCF margin8.4% (better)−31.0%
Return on equity15.9% (better)−26.9%
Return on invested capital36.9% (better)−90.4%
Financial health
Debt / equity0.490.39 (better)
Net debt / EBITDA−3.79–
Interest coverage2.5× (better)−44.1×
Current ratio2.92 (better)2.13
Altman Z-score6.3343.35 (better)
Piotroski F-score44
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions105%2.8%
Held by insiders9.3%0.67%
Insider net buying, 12 months−$11.1M−$10.7M (better)
Short interest, % of float15.9%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.